Records are supplied by study sponsors and investigators. A registry listing is not an endorsement or a guarantee of safety, availability or eligibility.
WCR feed checked: Nov 11, 2026.
RecruitingNCT06818643
Advanced Solid Tumors · Malignant Neoplasm
Phase 1 / Phase 218 years - Not specifiedMiami, Florida, United States +40 Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, n…
RecruitingNCT07645287
HIV-1-infection
Phase 218 years - Not specifiedMiami, Florida, United States +53 The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy (bictegravir/emtricitabine/tenofovir alafenam…
RecruitingNCT03618550
Hodgkin Lymphoma · Relapsed or Refractory Hodgkin Lymphoma
Phase 218 years - Not specifiedMiami, Florida, United States +9 The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
RecruitingNCT07099898
Neoplasms, Lung
Phase 318 years - Not specifiedMiami, Florida, United States +127 In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evalua…
RecruitingNCT07357727
Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Phase 318 years - Not specifiedMiami, Florida, United States +159 The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofib…
RecruitingNCT07430306
Systemic Lupus Erythematosus
Phase 318 years - 70 yearsMiami, Florida, United States +88 The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in …
RecruitingNCT07929792
Spinal Cord Injury · Amyotrophic Lateral Sclerosis · Chronic Ischemic Stroke · Tetraplegia/Tetraparesis
Not applicable18 years - Not specifiedMiami, Florida, United States The purpose of this study is to evaluate the safety and preliminary effectiveness of the N1 System, a fully implanted brain-computer interface placed in the motor cortex with the R1 Robot. The study builds on knowledge gained in a previous clinical i…
RecruitingNCT06806033
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Phase 218 years - Not specifiedMiami, Florida, United States +49 This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort A), and for glofitam…
RecruitingNCT07235059
Chronic Kidney Disease
Phase 118 years - 65 yearsMiami, Florida, United States +1 The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
RecruitingNCT01209000
Minimal Change Disease (MCD) · Membranous Nephropathy · Glomerulosclerosis, Focal Segmental
ObservationalNot specified - 80 yearsMiami, Florida, United States +31 Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) case…
RecruitingNCT06430801
Crohn's Disease
Phase 316 years - 80 yearsMiami, Florida, United States +402 The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in…
RecruitingNCT07650916
HIV
Phase 312 years - Not specifiedMiami, Florida, United States +83 This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Next page Retrieved from ClinicalTrials.gov: Nov 11, 2026. Overall study status may differ from a particular location’s status.
